FDA Inspection 1042533 — Braeburn Pharmaceuticals Inc.

Braeburn Pharmaceuticals Inc. — FEI 3012349378

The FDA completed an inspection of Braeburn Pharmaceuticals Inc. on Feb 8, 2018 in Princeton, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 2 citations were issued during this inspection. Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Feb 8, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Princeton, NJ (United States)

Additional details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
21360FDCA 505-1(f)(4)Failure to comply with REMS Implementation System
673221 CFR 314.80(c)(1)(i)Late submission of 15-day report

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.